Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-4066
      • ALG.APV-527
    • Scientific publications
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q1 2025
    • Preferential Rights Issue Q1 2024
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. Staff change
Key downloads
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025Alligator Bioscience AB reports financial results for Q1 2025 and provides a business updateAlligator Bioscience publishes Annual Report for 2024Bulletin from the extraordinary general meeting in Alligator Bioscience ABAlligator Bioscience AB reports full year financial results for 2024 and for Q4 2024 and provides a business update
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2021-04-30

Board member in Alligator Bioscience resigns at his own request

Lund, Sweden, April 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company's Board member Carl Borre ...
Continue reading
2021-03-18
Regulatory

Alligator Bioscience appoints Søren Bregenholt as new CEO

Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søre ...
Continue reading
2021-01-15

Alligator Bioscience appoints Chief Scientific Officer

Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark ...
Continue reading
2020-12-29

Alligator Bioscience recruits new Chief Medical Officer

Lund, Sweden, December 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina ...
Continue reading
2020-09-28

Alligator Bioscience appoints Gayle Mills as Chief Business Officer

Lund, Sweden, September 28, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today the appointment of Gayle Mills as Chief Bu ...
Continue reading
2020-06-15

Alligator Bioscience appoints new CFO

Lund, Sweden, June 15, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the appointment of Marie Svensson as Chief Fina ...
Continue reading
2020-03-05

Alligator Bioscience appoints Andreas Johannesson as interim Chief Financial Officer

Lund, Sweden, 5 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed inte ...
Continue reading
2019-12-11

CFO Per-Olof Schrewelius leaves Alligator Bioscience

Lund, Sweden, December 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that CFO (Chief Financial Officer) Per-Olo ...
Continue reading
2019-11-29

Alligator Bioscience AB appoints Chief Operating Officer

Lund, November 29, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX today announced that the company has appointed Dr Malin Carlsson as ...
Continue reading

Posts navigation

Older posts
Newer posts
  1. Startpage
  2. News
  3. Staff change
About Alligator

Alligator, a clinical-stage biotechnology company, develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
  • Glossary
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheeletorget 1
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2024 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all